• Explore /
  • Poster
  • / Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.

Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.

Abstract Poster

Authors

Judy Wang

Judy Sing-Zan Wang

Florida Cancer Specialists and Research Institute, Sarasota, FL

Judy Sing-Zan Wang , Minal A. Barve , E. Gabriela Chiorean , Patricia LoRusso , Kevin Dale Courtney , Dan Qi , Arturo Olguin , John Bullington , Megan Sardone , Vanessa Dunn , Shay Shemesh , Janice Chen , Christopher Brooks , Todd Michael Bauer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Other Novel Agents

Clinical Trial Registration Number

NCT02667873

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2560)

DOI

10.1200/JCO.2018.36.15_suppl.2560

Abstract #

2560

Poster Bd #

386

Abstract Disclosures

Similar Posters

First Author: Soohyeon Lee

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.

First Author: Jing Huang

First Author: Wang Yk

First Author: Toshio Shimizu